EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Defibrotide inhibits thrombin-dependent functions only at supratherapeutic concentrations

Shelley Choudhury, Thomas Girard, Renu Subramanian, Ryan Wagoner, Nathan Stitziel, Kristin Maher, Alireza R Rezaie, Kaushik Muralidharan, Bryce A. Kerlin, Jorge Di Paola

Blood Vessels, Thrombosis & Hemostasis · 2026-10 · 100233

DOI: 10.1016/j.bvth.2026.100233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-10. Verfasst von Shelley Choudhury und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH NCI.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease (VOD), results from cytotoxic injury to hepatic endothelial cells. Defibrotide (DF), a mixture of porcine DNA-derived single-stranded oligonucleotides (aptamers) and FDA-approved treatment for SOS/VOD, has been reported to have antithrombotic, fibrinolytic, and cytoprotective effects. However, animal studies required supratherapeutic dosing of DF to demonstrate in vivo antithrombotic effects. TBA and HD22 are anti-thrombin specific aptamers that target thrombin exosites I and II, respectively. Thrombin generates fibrin and, via protease activated receptors (PARs), induces platelet activation and inflammation which may contribute to SOS/VOD. We investigated DF’s inhibition of thrombin-induced PAR1-dependent cell-signaling, cell-based prothrombotic effects and plasma-based coagulation. Human platelets and immortalized EA.hy926 endothelial cells, with and without PAR1 deleted, were incubated with DF, thrombin exosite-binding aptamers, or controls prior to thrombin stimulation and assessment for aggregation, activation (via flow cytometry), calcium release, and/or permeability. Supratherapeutic levels of DF were required to inhibit thrombin-induced platelet activation and aggregation, PAR1-dependent EA.hy926 calcium mobilization and permeability and thrombin- and tissue factor-inudced coagulation. Biolayer interferometry (BLI) detected thrombin binding to immobilized PAR1 peptide and thrombin exocite-binding aptamers. DF disrupted thrombin binding to PAR1 peptide and exosite-binding aptamers. A mixture of unrelated oligonucleotides behaved similarly, to DF in all assays. DF’s inhibition of thrombin universally required concentrations above what is achieved therapeutically. DF’s inhibition of thrombin is not largely sequence independent. It is unlikely that DF’s effect on thrombin-dependent endothelial, platelet or plasma-based functions can explain its effectiveness in SOS/VOD.

Förderung

  • NIH NCI

Zitieren

APA

Choudhury, S., Girard, T., Subramanian, R., Wagoner, R., Stitziel, N., Maher, K., Rezaie, A. R., Muralidharan, K., Kerlin, B. A., & Paola, J. D. (2026). Defibrotide inhibits thrombin-dependent functions only at supratherapeutic concentrations. Blood Vessels, Thrombosis & Hemostasis, 100233. https://doi.org/10.1016/j.bvth.2026.100233

Vancouver

Choudhury S, Girard T, Subramanian R, Wagoner R, Stitziel N, Maher K, et al. Defibrotide inhibits thrombin-dependent functions only at supratherapeutic concentrations. Blood Vessels, Thrombosis & Hemostasis. 2026:100233. doi:10.1016/j.bvth.2026.100233

BibTeX
@article{Choudhury2026,
  author = {Choudhury, Shelley and Girard, Thomas and Subramanian, Renu and Wagoner, Ryan and Stitziel, Nathan and Maher, Kristin and Rezaie, Alireza R and Muralidharan, Kaushik and Kerlin, Bryce A. and Paola, Jorge Di},
  title = {Defibrotide inhibits thrombin-dependent functions only at supratherapeutic concentrations},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2026},
  pages = {100233},
  doi = {10.1016/j.bvth.2026.100233}
}
Kostenlos starten →